JIR
COLL icon

James Investment Research’s Collegium Pharmaceutical COLL Stock Holding History

James Investment Research’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$215K Sell
5,940
-1,170
-16% -$40K 0.02% 343
2026
Q1 		$235K Buy
7,110
+1,170
+20% +$49.5K 0.03% 320
2025
Q4 		$275K Buy
+5,940
New +$249K 0.03% 311

Other funds holding COLL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

James Investment Research's COLL Position: Q2 2026 in Review

James Investment Research reduced its Collegium Pharmaceutical (COLL) stake by 16% in Q2 2026, selling an estimated $40K and leaving 5,940 shares worth $215K. The position accounts for 0.02% of the portfolio, ranked #343.

James Investment Research first reported a position in COLL in Q4 2025 and has held it in 3 quarters since. The position peaked at $275K in Q4 2025. 279 funds tracked by Wall St. Rank hold COLL as of Q2 2026.

  • James Investment Research held 5,940 shares of Collegium Pharmaceutical worth $215K as of Q2 2026.
  • James Investment Research sold 1,170 Collegium Pharmaceutical shares in Q2 2026, an estimated $40K.
  • Collegium Pharmaceutical made up 0.02% of James Investment Research's portfolio in Q2 2026, its #343 holding.
  • James Investment Research first reported a position in Collegium Pharmaceutical in Q4 2025 and has held it in 3 quarters since.
  • James Investment Research's Collegium Pharmaceutical position peaked at $275K in Q4 2025.
  • 279 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q2 2026.

Based on James Investment Research's 13F filing for Q2 2026, filed 24 Jul 2026.